Maas Biolab, LLC is developing Mitogard intrathecal cyclosporin treatment for amyotrophic lateral sclerosis. Maas Biolab was founded in 1997 in Hawaii, and now resides in Santa Fe, New Mexico, under the operation of Michael Vickers. Maas has US Orphan drug designation for cyclosporine to treat ALS, and completed a $2.1 million SBIR grant from the NIH under PI Jenny Karlsson, PhD. Maas founded and is the single largest shareholder of NeuroVive Pharmaceutical.

EUGEN ROSENSTOCK-HUESSY FUND is a Vermont 501(c)3 non-profit corporation founded in 1976, that seeks to further interest in Eugen Rosenstock-Huessy’s life and work by making both his books and lectures widely accessible.

Mitochon Pharmaceuticals is a private pharmaceutical company, formed in 2014, that develops mitochondria-active drugs for a legion of serious, previously untreatable diseases. Our development programs include neurosurgical, neurological & neuromuscular diseases: Huntington’s Disease, Multiple Sclerosis/Optic Neuritis, Wolfram Syndrome, Epilepsy, Traumatic Brain Injury (TBI), Duchenne Muscular Dystrophy (DMD), Alzheimer’s Disease, and Parkinson Disease. Mitochon is led by a team of industry executives with over 120-years of combined experience and a passion to bring forward breakthrough drug therapies. www.mitochonpharma.com

Now renamed Abliva AB, NeuroVive Pharmaceutical AB was/is a Lund, Sweden pharmaceutical company started in 2000 by Maas Biolab, LLC, an American private company. NeuroVive is developing NeuroSTAT intravenous cyclosporine to treat traumatic brain injury, CicloMulsion intravenous cyclosporine to treat myocardial infarction, next generation sangamide mitochondrial protectants, and a new, broad antiviral family of drugs. NeuroVive is now an independent company listed on the NASDAQ OMX Nordic stock exchange in Stockholm (ticker: NVP.ST) and the OTC QX Market in the US (Ticker: NEVPF).

Gamma Knife radiosurgery

CyberKnife radiosurgery